Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
acetylcholine
acetylcholine receptor
acetylcholine receptor antibody
acetylcholinesterase
activities of daily living
advance directives
advances in neurology
adverse drug reaction
age associated memory impairment
aggression
agitation
algorithm
alpha methyltyrosine
Alzheimer's disease
Alzheimer's disease, behavioral symptoms
Alzheimer's disease, diagnosis of
Alzheimer's disease, driving with
Alzheimer's disease, early symptoms
Alzheimer's disease, familial
Alzheimer's disease, pathogenesis
Alzheimer's disease, preclinical
Alzheimer's disease, risk factors in
Alzheimer's disease, treating associated medical problems in
Alzheimer's disease, treatment of
amantadine
amitriptyline
amnesia
amphetamines
amyloid beta protein
amyloid imaging
analgesic
anesthesia, general
anesthesia, local
anorexia
antibiotics
antibiotics, neurologic complications with
anticholinergic drugs
anticholinergic drugs, side effects of
anticholinesterase
anticonvulsants
anticonvulsants, untoward effects of
antidepressant
antioxidant
antistriational muscle antibody
anxiety
apnea
apolipoprotein E
apomorphine
apraxia
apraxia, constructional
arthralgia
arthrogryposis multiplex
ataxia
ataxia, hereditary
atropine
atypical
autoimmune disease
autonomic dysfunction
azathioprine
baclofen
behavior
behavior, combative
behavioral disorder
Bell's phenomenon
benzodiazepine
beta adrenergic blocker
biological warfare
blepharospasm
Brueghel's syndrome
bulbar palsy
caloric testing
caloric testing, unconscious patient
camphor
carbamazepine
caregiver
CAT scan, emission
CAT scan, emission, abnormal
cerebellar atrophy, primary
cerebrospinal fluid, elevated protein of
chemical weapons
chlorambucil
choline chloride
cholinergic crisis
cholinergic drug
chorea
chronic fatigue syndrome
clonazepam
clozapine
clubfoot as related to neurologic disease
cocaine
cognition
Collier's sign
coma
complications
conflict of interest
confusion
congenital myasthenic syndromes
consanguinity
contrast agents, neurotoxicity of
controversies in neurology
cost
cost effectiveness
critical care unit
cyclophosphamide
cyclosporine
cytokines
deanol
DEET
delay in diagnosis
delirium
delusion
dementia
dementia, cerebrovascular disease causing
dementia, diagnostic classification
dementia, diagnostic evaluation of
dementia, prevention of
dementia, treatment of
dementia, unknown etiology
deprenyl
depression
developmental retardation
diarrhea
differential diagnosis
dilantin
diplopia
donepezil
dopamine
dopamine agonist
dopamine antagonist
driving
drug abuse
drug abuse, neurologic complications of
drug induced neurologic disorders
drug interactions
drug overdose
drug withdrawal
dysnomia
dystonia
dystonia, drug induced
dystonia, face
dystonic reaction, acute
eating disorder
echolalia
efficacy
electroconvulsive therapy
electromyogram
electromyogram, decremental response
emergencies, neurologic
enzyme inhibition
ephedrine
ergonovine
evidence-based research
executive dysfunction
exercise
exome sequencing
eye closure
eye, pain in
facial hallucinations
facial weakness
falling
fatigue
felbamate
folic acid
Friedreich's ataxia
galantamine
gammaglobulin therapy, intravenous
gene
gene mutation
genetic neurologic disorders
Gilles de la Tourette syndrome
ginkgo biloba
ginseng
Gulf War syndrome
hallucination
haloperidol
headache
hepatitis
heralding manifestation
herbs
high arched palate
hoarding
Huntington's chorea
hyperbaric oxygen
hyperbaric treatment
iatrogenic neurologic disorders
immunologic disease
immunosuppressive agents
inappropriate behavior
insect repellent
insecticides
insomnia
intellectual deficit
interferon
intestinal pseudoobstruction
irritability
lacrimation
lecithin
level of consciousness, decreased
Lewy body disease, diffuse
lid abnormalities
lid closure, weakness of
lid twitch
lidocaine
lithium
liver disease
liver function enzymes
malabsorption
malformation, CNS, congenital
managed care
maprotiline
mediastinum, mass of
memantine
memory
memory, defect of recent
memory, disorder, treatment of
memory, impairment of
memory, impairment of, subjective
mestinon
metrifonate
microcephaly
mild cognitive impairment
Mini Mental Status Examination
miosis
misdiagnosis
mongolism
mortality
movement disorder
movement disorder, drug induced
MRI, abnormal
multiple sclerosis
muscle biopsy
muscle pain
muscle weakness
muscle weakness, proximal
myasthenia gravis
myasthenia gravis, anticholinesterase malabsorption in
myasthenia gravis, anticholinesterase serum levels in
myasthenia gravis, classification
myasthenia gravis, diagnosis
myasthenia gravis, differential diagnosis
myasthenia gravis, drug induced
myasthenia gravis, etiology of
myasthenia gravis, infantile and juvenile
myasthenia gravis, misdiagnosis of
myasthenia gravis, neuromuscular junction in
myasthenia gravis, ocular
myasthenia gravis, presenting manifestations
myasthenia gravis, prognosis of
myasthenia gravis, receptor site in
myasthenia gravis, remission of
myasthenia gravis, seronegative
myasthenia gravis, thymectomy in
myasthenia gravis, treatment of
myasthenia gravis, unmasked
myasthenic crisis
mycophenolate
nalidixic acid
narcotic analgesics
nasal speech
nausea and vomiting
nerve agents
neuroleptic
neuroleptic malignant syndrome
neuroleptic, atypical
neurologic consultation
neurologic disease
neurologic disease, diagnoses of
neurologic signs
neurologic symptoms
neuromuscular blockade
neuromuscular disease, electrodiagnosis of
neuromuscular junction
neuromuscular junction, abnormality of
neuroophthalmology
neuropathology
neuropathy
neuropathy, toxic
neurotoxic
neurotoxin
NMDA antagonists
nonsteroidal anti-inflammatory drug
nursing home
nystagmus
occupational neurologic disorders
ocular motility, disorders of
oculocephalic reflex
olanzapine
old age, neurology of
opened mouth
ophthalmoplegia
ophthalmoplegia, total
pain, abdominal
papaverine
paranoia
Parkinson disease
Parkinson disease, dementia with
Parkinson disease, nonmotor problems of
Parkinsonism syndrome
patient information and support
penicillamine
penicillin
personality change
phencyclidine poisoning
phenobarbital
phenothiazine
phenylpropanolamine
physostigmine
pimozide
Pisa syndrome
Pittsburgh Compound B
plasmapheresis
poison, neurologic problems with
poison, organophosphate
polyneuropathy
postural abnormality
practice guidelines
pregnancy, neurologic complications in
premarin
prevention of neurologic disorders
prognosis
propranolol
prosopometamorphopsia
prostigmine
pseudointernuclear ophthalmoplegia
psychiatric disorder
psychiatric problems in neurologic disorders
psychological testing
psychomotor retardation
psychosis
psychotic behavior
ptosis
ptosis, bilateral
pupil, dilated, bilateral
quality of life
quetiapine
quinine
radiotracer imaging
repetitive nerve stimulation
repetitive questioning
reserpine and reserpine like drugs
respiratory failure
respiratory paralysis, pharmacologic
review article
Reye's syndrome
rhinorrhea
risk factors
risk-benefit assessment
risperidone
rivastigmine
rummaging
saccadic eye movements
saccadic eye movements, abnormal
safety
salivation, excessive
Sarin
seizure
seizure, drug-induced
selective serotonin reuptake inhibitors
senile plaques
seronegative
serum alanine aminotransferase
shadowing
single photon emission computed tomography
single-fiber electromyography
sleep
sleep pathology and physiology
snake bite
Soman
spinocerebellar ataxia type 1
spinocerebellar degeneration
stereotyped behavior
steroid
steroid therapy, CNS treatment and complications with
sumatriptan
sympathomimetic drugs
Tabun
tachycardia
tachypnea
tardive dyskinesia
tardive dyskinesia, treatment of
tensilon
tensilon test, false negative
tensilon test, false positive
tensilon test, paradoxical
tetrabenazine
tetrahydroaminoacridine
thymectomy
thymoma
thymus and neuromuscular function
toxins, nervous system
treatment of neurologic disorder
treatment, non-pharmacologic
upgaze, paralysis of
vaccination, neurologic complications with
visuospatial disturbance
vitamin E
vitamin K
voice, abnormality of
VX
wandering
war
weakness
weakness, fatiguable
weakness, generalized
weakness, proximal
weight loss
white matter disease
workup
Showing articles 450 to 500 of 871 << Previous Next >>

Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010

Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010

Practice Parameter: Treatment of Nonmotor Symptoms of Parkinson Disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:924-931, Zesiewicz,T.A.,et al, 2010

Neuromuscular Symptoms and Elevated Creatine Kinase After Statin Withdrawal
NEJM 362:564-565, Echaniz-Laguna,A.,et al, 2010

Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010

Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010

Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010

Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010

Posterior Reversible Encephalopathy Syndrome After Rituximab Infusion in Neuromyelitis Optica
Neurol 74:1471-1473, S�nchez-Carteyron,A., et al, 2010

Treatment of Refractory Neurosarcoidosis with Infliximab
JNNP 81:241-246, Santos,E., et al, 2010

Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010

A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010

What if the sexual headache is not a joke?
BJMP 3:304-308, Redelman, M., 2010

Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009

Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009

Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009

Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009

Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009

Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009

Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009

Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009

Diagnosis and Management of Neuropathic Pain
BMJ 339:391-395, Freynhagen,R. &Bennett,M.I., 2009

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009

Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009

Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009

Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009

Diagnosis and New Treatment in Muscle Channelopathies
JNNP 80:360-365, Meola,G.,et al, 2009

Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009

Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009

Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009

Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009

Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009

Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009

Spontaneous Isolated Convexity Subarachnoid Hemorrhage: Presentation, Radiological Findings, Differential Diagnosis, and Clinical Course
J Neurosurg 109:1034-1041, Refai, D.,et al, 2008

A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy
Mod Rheumatol 18:399-402, Kameda, T.,et al, 2008

Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease
Stroke 39:497-502, Vergouwen,M.D.I.,et al, 2008

Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stoke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)
Stroke 39:89-99, Adams,H.P.,Jr.,et al, 2008

B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008

Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008

Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008

Statin Therapy for Stroke Prevention
Stroke 39:1042-1048, Nassief,A. &Marsh,J.D., 2008

Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008

Response of Anti-NMDA Receptor Encephalitis Without Tumor to Immunotherapy Including Rituximab
Neurol 71:1921-1923, Ishiura,H.,et al, 2008

Statin Induced Myopathy
BMJ 337:1159-1162, Sathasivam,S. &Lecky,B., 2008



Showing articles 450 to 500 of 871 << Previous Next >>